Your Source for Venture Capital and Private Equity Financings

Apothekary Closes Funding Round

2021-11-18
FALLS CHURCH, VA, Apothekary announces today the closing of a multi-million-dollar funding round,
Apothekary, the plant-based farmacy that delivers clean, natural alternatives to traditional over-the-counter drugs and supplements in an easy-to-use form, announces today the closing of a multi-million-dollar funding round, spearheaded by Apothekary founder, Shizu Okusa, a second-time founder, and backed by esteemed industry investors. The funds will enable the brand to further accelerate growth, retail expansion with partners in UK and Canada, grow their team, and execute on their robust product innovation pipeline and double down on their brand and customer experience.

The round has attracted individual entrepreneurs as investors with 80% of participants being founders themselves, including seasoned executives from the pharmaceutical, beauty, to real estate industries. Select investors from the round include industry luminaries such as Bryan Goldberg (Founder of Bustle Digital Group), John Montalbano (Former CEO of RBC Global Asset Management), Eric Patel (Current and Former Board of Directors Chair for brands including SmartSweets, Daiya, Cymax and more) and many more.

Open your medicine cabinet. What do you see? Likely products with ingredients Apothekary would never allow in their pantries, but they accept their place in medicine. It's time to ditch the pharmacy for the farmacy. Meet Apothekary, the creators of the plant-based farmacy. Apothekary prefers plants over pills, and thinks you will too. The goal, always, is to keep toxins out, not bring them in, and they believe that through plant-based medicine they have the ability to unite the mind, body and soul into balance. This is a game-changing concept for the industry through a highly personalized approach to wellness that puts plants and people first.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading